Fig. 8: Interrogation of siRNA conjugate lipid tail presence. | Nature Communications

Fig. 8: Interrogation of siRNA conjugate lipid tail presence.

From: Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy

Fig. 8

a Structures of the si < (EG18L2) variants to confirm the function of the lipids. b Treatment schematic showing i.v. dosing of conjugates to tumor-bearing mice. c Biodistribution of Cy5-labeled siRNA conjugates measured by epifluorescence 18 h after 1 mg/kg intravenous injection. Significance was assessed by two-way ANOVA with Tukey’s multiple comparisons (n = 4–6). d Percent Cy5 positive tumor cells determined by flow cytometry. e Relative luciferase activity of tumor lysates after 3 × 2 mg/kg intravenous injections of siRNA conjugates targeting firefly luciferase over the course of one week. Significance assessed by one-way ANOVA with Tukey’s multiple comparisons (n = 4–7). Significance compared to si<(EG18L)2 is displayed. Each bar represents the average value (± S.D.), and each point represents values measured for each independent sample.

Back to article page